Hansoh Pharma drug meets trial endpoints, shares jump
Shares of Hansoh Pharmaceutical Group rose 4.3% to HK$35.76, their highest level since September 9, after the company said its phase III clinical trial of HS-10374 in treatment of moderate-to-severe plaque psoriasis met co-primary and multiple secondary endpoints. The drug demonstrated a favourable safety and tolerabil